Cargando…

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin

BACKGROUND: Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the results of eradicati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akkerman-Nijland, Anne M., Yousofi, Mina, Rottier, Bart L., Van der Vaart, Hester, Burgerhof, Johannes G. M., Frijlink, Henderik W., Touw, Daan J., Koppelman, Gerard H., Akkerman, Onno W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016310/ https://www.ncbi.nlm.nih.gov/pubmed/32046620 http://dx.doi.org/10.1177/1753466620905279

Ejemplares similares

Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2023)

Colistin dry powder inhalation with the Twincer™: An effective and more patient friendly alternative to nebulization
por: Akkerman-Nijland, A. M., et al.
Publicado: (2020)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers
por: Lexmond, Anne J., et al.
Publicado: (2014)

Prerequisites for a dry powder inhaler for children with cystic fibrosis
por: Lexmond, Anne J., et al.
Publicado: (2017)

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
por: Sibum, Imco, et al.
Publicado: (2019)

Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers
por: de Reus, Y. A., et al.
Publicado: (2022)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
por: Panguluri, Srilekha, et al.
Publicado: (2017)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence
por: Hamed, Kamal, et al.
Publicado: (2017)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease
por: Luinstra, Marianne, et al.
Publicado: (2019)

Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge
por: Tomar, Jasmine, et al.
Publicado: (2018)

Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine
por: Sibum, Imco, et al.
Publicado: (2019)

Performance Testing of a Homemade Aerosol Generator for Pulmonary Administration of Dry Powder Formulations to Mice
por: Heida, Rick, et al.
Publicado: (2023)

Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops(®) High Dose Dry Powder Inhalation Device While Maintaining Dispersibility
por: Sibum, Imco, et al.
Publicado: (2020)

Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation
por: Gauthier, Timothy P., et al.
Publicado: (2015)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Ultrastructure imaging of Pseudomonas aeruginosa lawn biofilms and eradication of the tobramycin-resistant variants under in vitro electroceutical treatment
por: Lochab, Varun, et al.
Publicado: (2020)

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
por: Hamed, Kamal, et al.
Publicado: (2017)

A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms
por: Schütz, Christian, et al.
Publicado: (2021)

Efficacy of inhaled tobramycin in severe nosocomial pneumonia
por: Kuzovlev, A, et al.
Publicado: (2012)

Inhaled tobramycin for the treatment of nosocomial pneumonia in sepsis
por: Kuzovlev, A, et al.
Publicado: (2014)

Drug Content Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation
por: Grasmeijer, Floris, et al.
Publicado: (2013)

Mixing Time Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation
por: Grasmeijer, Floris, et al.
Publicado: (2013)

Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration
por: Heida, Rick, et al.
Publicado: (2023)

Correction: Mixing Time Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation
por: Grasmeijer, Floris, et al.
Publicado: (2013)

Adherence with tobramycin inhaled solution and health care utilization
por: Briesacher, Becky A, et al.
Publicado: (2011)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Early preventive administration of inhaled tobramycin in severe polytrauma
por: Kuzovlev, A, et al.
Publicado: (2015)

Squalenyl Hydrogen Sulfate Nanoparticles for Simultaneous Delivery of Tobramycin and an Alkylquinolone Quorum Sensing Inhibitor Enable the Eradication of P. aeruginosa Biofilm Infections
por: Ho, Duy‐Khiet, et al.
Publicado: (2020)

Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance
por: Beaudoin, T., et al.
Publicado: (2017)

Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process
por: Gareb, Bahez, et al.
Publicado: (2019)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

RpoN Promotes Pseudomonas aeruginosa Survival in the Presence of Tobramycin
por: Viducic, Darija, et al.
Publicado: (2017)

Surface Engineering Methods for Powder Bed Printed Tablets to Optimize External Smoothness and Facilitate the Application of Different Coatings
por: Nguyen, Khanh T. T., et al.
Publicado: (2023)

Itaconic Acid Increases the Efficacy of Tobramycin against Pseudomonas aeruginosa Biofilms
por: Ho, Duy-Khiet, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b697ah005re9jmf0helec0352m